Published on 22 Apr 2024 on Benzinga
Monday, Corcept Therapeutics Incorporated CORT released results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of endogenous Cushing’s syndrome (hypercortisolism).
GRACE has two parts.